Navigation Links
New Data Confirm That Use of Levemir Can Limit Weight Gain

lin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 2005; 7(1):73–82

16 Pieber T et al. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabetic Medicine 2005; 22(7):850–57

17 Standl E et al. The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of type 1 diabetes. Diabetes Technology Therapeutics 2004; 6(5):579–88

18 Home P et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 2004; 27(5):1081–87

19 Hermansen K et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47(4):622–29

20 Rašlova K et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004; 66(2):193–201

21 Haak T et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005; 7(1):56–64

22 Robertson K et al. Insulin detemir compared with NPH insulin in children and adolescent with type 1 diabetes, Diabetes Medicine 2007; 24(1):27

23 Pieber TR et al. Insulin detemir plus insulin aspart is associated with less risk of major as well as nocturnal hypoglycaemia than insulin glargine plus insulin aspart at comparable levels of glycaemic control in type 1 diabetes. Diabetic Medicine 2007. In press.

24 Klein O et al. A
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
2. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
3. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
4. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
5. New Data Confirms Significant Improvement of Disease Signs and Symptoms in Patients with Rheumatoid Arthritis
6. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
7. New Research Confirms the Benefit of Extended-Release Dipyridamole Plus ASA for Preventing Recurrent Stroke in Low- and High-Risk Patients
8. New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release Tablets as Effective Treatment for Schizophrenia
9. Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral Approach to Treating Inflammatory Diseases
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New Data Confirm That Use Levemir Can Limit Weight Gain
(Date:12/14/2009)... Pa., Dec. 14 Fujirebio Diagnostics Inc., ... Company of the Year by the Eastern Technology ... Hilton Hotel in Philadelphia on Thursday, December 3, ... is the Philadelphia region,s largest technology and life ... of the Technology and Life Sciences Community, the ...
(Date:12/14/2009)... 14 In response to an ... in which the Agency recommended that healthcare facilities ... sterile processing system, hospitals throughout the U.S. are ... to that product. According to the FDA, STERIS ... that may affect the safety or the effectiveness ...
(Date:12/14/2009)... Dec. 14 Following is a statement ... Consumer Healthcare Products Association (CHPA), regarding today,s release ... Monitoring the Future survey: ,, "Findings released today ... to the need for continued efforts to educate ... to talk to their teens about medicine abuse. ...
Breaking Medicine Technology:Fujirebio Diagnostics Named Life Sciences Company of the Year 2ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 2ECRI Institute Issues Steris System 1 High Priority Alert and Recommendations: Free Guidance to Help Hospitals Map out Transition to Alternative Reprocessing Methods 3Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 2Statement From the Consumer Healthcare Products Association(CHPA) on Annual Monitoring the Future Survey on Drug Abuse 3People who wear rose colored glasses see more University of Toronto study shows 47792 1People who wear rose colored glasses see more University of Toronto study shows 47792 2Effective over the counter prostate cancer test kit likely in next few years 47790 1Effective over the counter prostate cancer test kit likely in next few years 47790 2Diet may reduce risk of prostate cancer 47788 1
... September 24 Arpida,Ltd. (SWX: ARPN) today announced ... switch trial with oral iclaprim in patients with,complicated ... trial was designed as a multi-centre, double-blind comparative,study. ... the first two days of treatment and were ...
... Inc. (Amex: PTN ) announced it presented ... a novel, long-acting natriuretic peptide,receptor A (NPRA) agonist ... heart failure, at the 12th Annual Scientific Meeting ... Metro Toronto Convention,Centre, Toronto, Ontario, Canada on September ...
Other Medicine Technology:Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim 2Arpida Completes Enrolment in Phase II "Intravenous-to-Oral" Switch Trial With Oral Iclaprim 3Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America 2Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America 3
(Date:12/14/2009)... -- Pepsi Bottling Group, ArvinMeritor, Inc., Marathon Oil ... the major employers that implemented Thomson Reuters Informed ... make better decisions about their benefits. ,, The ... of their families, use of healthcare services and ... information, employees can determine which of the available ...
(Date:12/14/2009)... ATLANTA, Dec. 14 Americold Realty Trust ("Americold") ... on Form S-11 with the U.S. Securities and Exchange ... offering of its common shares. The number of shares ... offering have not yet been determined. The common shares ... be sold by Americold. ,, The joint book-running ...
(Date:12/14/2009)... -- Haemonetics Corporation (NYSE: HAE ) ... legal action to stop Fenwal Inc.,s continued patent ... collection kits, using a modified separation chamber. ... Haemonetics, patent and the injunction entered by the ... after December 1, 2010. According to statements ...
(Date:12/14/2009)... 14 The National Organization for Rare Disorders ... end to lifetime and annual health insurance caps. ... a newspaper distributed widely on Capitol Hill, NORD said ... would allow caps to continue for most Americans, contrary ... health care reform and welcomes the promises made by ...
(Date:12/14/2009)... Tough Enough To Wear Pink(TM) (TETWP), the grassroots ... fifth anniversary at the signature Tough Enough To ... Rodeo (Wrangler NFR) in Las Vegas. While pink ... the support of the western industry and rodeo ... pink shirts, hats, bracelets and more. ,, ...
Breaking Medicine News(10 mins):Health News:Corporations, Universities and State Governments Deploy Thomson Reuters Solution to Improve Employees' Benefit Selection Process 2Health News:Americold Realty Trust Files Registration Statement for Proposed Initial Public Offering 2Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 2Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 3Health News:NORD Calls for Immediate End to Lifetime Insurance Caps 2Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 2Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 3Health News:Tough Enough To Wear Pink(TM) Celebrates Fifth Anniversary 4
... had 32% more microbleeds in several different areas, study finds ... likely than whites to have small bleeds within the brain, ... new study. , Compared with whites, blacks had 32 ... tied to increased odds of having a stroke. Blacks were ...
... Matthew L. Myers was released today by the Campaign ... has announced plans to,test-market three new smokeless tobacco products ... flavors and have slick, colorful,packaging similar to gum and ... also carry the name of RJR,s Camel cigarettes, one ...
... Oct. 8 Accuray,Incorporated (Nasdaq: ARAY ), a ... the first CyberKnife(R) Robotic Radiosurgery System in,the Kingdom of ... Specialist Hospital and Research Center in Riyadh. It is ... East region., King Faisal Specialist Hospital, the leading ...
... Scientific,(NYSE: BSX ) announced today it expects to ... it plans to report on October 23rd., As ... from Abbott Laboratories (NYSE: ABT ) in July, ... endovascular,solutions businesses. As a result, the Company expects to ...
... cardiovascular trouble , , WEDNESDAY, Oct. 8 (HealthDay News) -- ... white blood cells might someday help doctors determine the ... report. , The finding is interesting in part because ... a new American Heart Association journal, Circulation: Cardiovascular ...
... 10,000 pediatricians,and other health care professionals are expected to ... and Exhibition (NCE),at the Hynes Convention Center in Boston., ... 12, 11:50 a.m.-12:10 p.m., The ABC Ballroom at ... a huge recording studio as over 2,500,pediatricians get to ...
Other Medicine News:Health News:R.J. Reynolds' New Smokeless Products Will Appeal to Children and Show Need for FDA Regulation of Tobacco Products 2Health News:First CyberKnife in Saudi Arabia to be Installed at Prestigious King Faisal Specialist Hospital and Research Center 2Health News:First CyberKnife in Saudi Arabia to be Installed at Prestigious King Faisal Specialist Hospital and Research Center 3Health News:First CyberKnife in Saudi Arabia to be Installed at Prestigious King Faisal Specialist Hospital and Research Center 4Health News:Boston Scientific Announces Third Quarter Adjustments 2Health News:Boston Scientific Announces Third Quarter Adjustments 3Health News:Boston Scientific Announces Third Quarter Adjustments 4Health News:Boston Scientific Announces Third Quarter Adjustments 5Health News:Blood Cell Genes May Signal Heart Disease 2Health News:AAP National Conference and Exhibition October 10-14, 2008 2Health News:AAP National Conference and Exhibition October 10-14, 2008 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: